CTSO · Insider Trading
Cytosorbents Corp.
Every open-market purchase and sale reported by CTSO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-16 | Alan D. Sobel | Director | Buy | +2,500 | +$15.25K |
| 2026-09-16 | Phillip P. Chan | Chief Executive Officer | Buy | +3,774 | +$22.64K |
| 2026-09-16 | Vincent Capponi | President and COO | Buy | +2,073 | +$12.54K |
| 2026-09-09 | Phillip P. Chan | Chief Executive Officer | Buy | +200,000 | +$70.00K |
| 2026-06-16 | Peter J Mariani | Chief Financial Officer | Buy | +100,000 | +$44.00K |
| 2026-06-15 | Phillip P. Chan | Chief Executive Officer | Buy | +261,469 | +$104.90K |
| 2025-11-20 | Phillip P. Chan | Chief Executive Officer | A | +100,000 | +$64.00K |
| 2025-08-08 | Edward Raymond Jones | Director | A | — | — |
| 2025-08-08 | Vincent Capponi | President and COO | A | +89,100 | — |
| 2025-08-08 | Phillip P. Chan | Chief Executive Officer | A | +105,600 | — |
| 2025-08-08 | Michael G. Bator | Director | A | — | — |
| 2025-08-08 | Peter J Mariani | Chief Financial Officer | A | +71,500 | — |
| 2025-08-08 | Jiny Kim | Director | A | — | — |
| 2025-08-08 | Alan D. Sobel | Director | A | — | — |
| 2025-08-08 | Efthymios Deliargyris | Chief Medical Officer | A | +70,000 | — |
| 2025-03-04 | Michael G. Bator | Director | O | +10,000 | +$11.30K |
| 2025-02-26 | Phillip P. Chan | Chief Executive Officer | O | +34,168 | +$38.61K |
| 2025-02-26 | Vincent Capponi | President and COO | O | +12,000 | +$13.56K |
| 2025-02-26 | Peter J Mariani | Chief Financial Officer | O | +32,625 | +$36.87K |
| 2025-02-26 | Alan D. Sobel | Director | O | +21,950 | +$24.80K |
| 2025-01-22 | Michael G. Bator | Director | X | +15,879 | +$15.88K |
| 2025-01-22 | Peter J Mariani | Chief Financial Officer | X | +32,625 | +$32.62K |
| 2025-01-22 | Efthymios Deliargyris | Chief Medical Officer | X | +16,233 | +$16.23K |
| 2025-01-22 | Alan D. Sobel | Director | X | +21,950 | +$21.95K |
| 2025-01-22 | Vincent Capponi | President and COO | X | +31,760 | +$31.76K |
| 2025-01-22 | Phillip P. Chan | Chief Executive Officer | X | +90,832 | +$90.83K |
| 2024-12-16 | Peter J Mariani | Chief Financial Officer | Buy | +20,000 | +$19.29K |
| 2024-12-13 | Peter J Mariani | Chief Financial Officer | Buy | +31,363 | +$27.97K |
| 2024-10-08 | Vincent Capponi | President and COO | A | +150,000 deriv. | — |
| 2024-10-08 | Efthymios Deliargyris | Chief Medical Officer | A | +150,000 deriv. | — |
| 2024-08-16 | Peter J Mariani | Chief Financial Officer | A | +350,000 | — |
| 2024-04-04 | Alan D. Sobel | Director | A | +22,000 deriv. | — |
| 2024-04-04 | Michael G. Bator | Director | A | +44,000 deriv. | — |
| 2024-04-04 | Edward Raymond Jones | Director | A | +22,000 deriv. | — |
| 2024-04-04 | Efthymios Deliargyris | Chief Medical Officer | A | +61,000 | — |
| 2024-04-04 | Kathleen P. Bloch | Chief Financial Officer | A | +65,000 | — |
| 2024-04-04 | Vincent Capponi | President and COO | A | +81,000 | — |
| 2024-04-04 | Phillip P. Chan | Chief Executive Officer | A | +96,000 | — |
| 2024-04-04 | Jiny Kim | Director | A | +22,000 deriv. | — |
| 2024-04-02 | Efthymios Deliargyris | Chief Medical Officer | A | +47,088 deriv. | — |
| 2024-04-02 | Kathleen P. Bloch | Chief Financial Officer | A | +49,038 deriv. | — |
| 2024-04-02 | Phillip P. Chan | Chief Executive Officer | A | +129,998 deriv. | — |
| 2024-04-02 | Vincent Capponi | President and COO | A | +48,923 deriv. | — |
| 2023-12-15 | Kathleen P. Bloch | Chief Financial Officer | Buy | +37,594 | +$50.00K |
| 2023-12-15 | Alan D. Sobel | Director | Buy | +22,557 | +$30.00K |
| 2023-12-15 | Jiny Kim | Director | Buy | +7,519 | +$10.00K |
| 2023-12-15 | Efthymios Deliargyris | Chief Medical Officer | Buy | +22,557 | +$30.00K |
| 2023-12-15 | Edward Raymond Jones | Director | Buy | +7,519 | +$10.00K |
| 2023-12-15 | Michael G. Bator | Director | Buy | +37,594 | +$50.00K |
| 2023-12-15 | Vincent Capponi | President & COO | Buy | +18,797 | +$25.00K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Phillip P. Chan | Chief Executive Officer | 100,996 | $585.78K |
| Vincent Capponi | President and COO | 40,114 | $232.66K |
| Peter J Mariani | Chief Financial Officer | 31,906 | $185.05K |
| Efthymios Deliargyris | Chief Medical Officer | 23,651 | $137.18K |
| Alan D. Sobel | Director | 9,387 | $54.44K |
| Michael G. Bator | Director | 7,564 | $43.87K |
| Edward Raymond Jones | Director | 4,442 | $25.76K |
| Jiny Kim | Director | 3,891 | $22.57K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CTSO quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.